WINTON GROUP Ltd Buys 113,951 Shares of TG Therapeutics, Inc. $TGTX

WINTON GROUP Ltd lifted its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 1,031.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 125,000 shares of the biopharmaceutical company’s stock after acquiring an additional 113,951 shares during the period. WINTON GROUP Ltd owned 0.08% of TG Therapeutics worth $4,516,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of TGTX. Royal Bank of Canada increased its stake in TG Therapeutics by 16.4% in the first quarter. Royal Bank of Canada now owns 75,692 shares of the biopharmaceutical company’s stock valued at $2,985,000 after purchasing an additional 10,660 shares in the last quarter. NewEdge Advisors LLC boosted its position in shares of TG Therapeutics by 9.6% during the 1st quarter. NewEdge Advisors LLC now owns 7,593 shares of the biopharmaceutical company’s stock worth $299,000 after purchasing an additional 665 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of TG Therapeutics by 21.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company’s stock valued at $75,683,000 after buying an additional 345,059 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in TG Therapeutics by 5.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 287,059 shares of the biopharmaceutical company’s stock valued at $11,319,000 after buying an additional 14,689 shares in the last quarter. Finally, Envestnet Asset Management Inc. increased its position in TG Therapeutics by 2.8% in the 2nd quarter. Envestnet Asset Management Inc. now owns 51,682 shares of the biopharmaceutical company’s stock valued at $1,860,000 after buying an additional 1,422 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have issued reports on TGTX. Cantor Fitzgerald reiterated an “overweight” rating on shares of TG Therapeutics in a report on Wednesday, January 14th. JPMorgan Chase & Co. decreased their price objective on TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating for the company in a report on Monday, February 2nd. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of TG Therapeutics in a research report on Monday, December 29th. Wall Street Zen cut TG Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Finally, The Goldman Sachs Group lifted their price target on shares of TG Therapeutics from $37.00 to $39.00 and gave the company a “neutral” rating in a research report on Thursday, January 15th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $50.00.

TG Therapeutics Price Performance

Shares of NASDAQ TGTX opened at $29.19 on Tuesday. The stock has a market cap of $4.66 billion, a price-to-earnings ratio of 10.54 and a beta of 1.87. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.29 and a current ratio of 4.10. TG Therapeutics, Inc. has a fifty-two week low of $25.28 and a fifty-two week high of $46.48. The firm’s 50-day simple moving average is $29.65 and its 200 day simple moving average is $31.52.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.21). The company had revenue of $192.57 million for the quarter, compared to the consensus estimate of $192.15 million. TG Therapeutics had a return on equity of 101.12% and a net margin of 72.56%.The business’s revenue for the quarter was up 78.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.15 earnings per share. As a group, research analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.